Welcome to our dedicated page for Bioharvest news (Ticker: CNVCF), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. (CNVCF) is a biotechnology innovator leveraging patented Botanical Synthesis technology to transform plant-based molecule production. This news hub provides investors and industry stakeholders with timely updates on corporate developments, scientific breakthroughs, and strategic initiatives driving the company's growth in nutraceuticals and contract manufacturing.
Access comprehensive coverage of BioHarvest's progress across key areas including VINIA® product expansions, CDMO partnership announcements, and manufacturing facility upgrades. The page aggregates official press releases and verified news about financial results, clinical research outcomes, and sustainability achievements.
Key content categories include updates on the company's dual revenue streams, technological advancements in Botanical Synthesis, and regulatory milestones. Users will find information about BioHarvest's Yavne production facility expansion, strategic collaborations in pharmaceutical development, and consumer product innovations.
Bookmark this page for streamlined access to CNVCF's evolving story in sustainable biotechnology. Check regularly for authoritative updates on operational milestones and market positioning directly from corporate sources and verified financial news outlets.
BioHarvest Sciences Inc. (CSE: BHSC) announced strong Q3 2021 results, reporting VINIA® sales of USD 688K, a 44% increase from Q2 and a remarkable 1,198% growth compared to Q3 2020. In Israel, sales orders reached USD 452K, while USD 236K came from the U.S. pilot program, marking 251% growth over Q2. The company is preparing to launch a new manufacturing facility in Israel to meet increasing demand. Financing activities raised USD 3.48M through private placements and USD 4.41M from warrants, supporting its growth initiatives.
